Table 2.

The correlation between mRNA levels of E2Fs and clinical and molecular criteria of BC patients

Criteria	E2F1			E2F2		E2F3		E2F4		E2F5		E2F6		E2F7		E2F8
	No.a	mRNA	P-value	mRNA	P-value	mRNA	P-value	mRNA	P-value	mRNA	P-value	mRNA	P-value	mRNA	P-value	mRNA	P-value
Age
≤51	1,361	–	0.9623	–	0.0284	–	<0.0001	–	0.5265	–	0.0377	–	0.0004	–	0.8497	–	0.3461
>51	2,142	–		↓		↓		–		↓		↓		–		–
Nodal status
−	2,447	–	0.4376	–	0.1055	–	0.7359	–	0.2055	–	0.0246	–	0.8244	–	0.1139	–	0.1536
+	1,509	–		–		–		–		↑		–		–		–
ER (IHC)
−	1,525	–	<0.0001	–	<0.0001	–	<0.0001	–	0.0001	–	<0.0001	–	0.4174	–	<0.0001	–	<0.0001
+	3,923	↓		↓		↓		↓		↓		–		↓		↓
PR (IHC)
−	946	–	<0.0001	–	<0.0001	–	<0.0001	–	0.0097	–	0.0919	–	0.0282	–	0.0002	–	<0.0001
+	1,439	↓		↓		↓		↓		–		↓		↓		↓
HER2 (IHC)
−	1,409	–	0.0083	–	0.3372	–	0.0293	–	0.8335	–	0.6897	–	0.9495	–	0.0012	–	<0.0001
+	201	↑		–		↑		–		–		–		↑		↑
Triple-negative BC (TNBC)
Not	4,099	–	<0.0001	–	<0.0001	–	<0.0001	–	0.9164	–	0.0007	–	0.8832	–	0.0251	–	<0.0001
TNBC	374	↑		↑		↑		–		↑		–		↑

Note:

^aThe number of patients was based on the group of E2F1 and the exact number of patients in other groups may be a little different.

Abbreviations: E2Fs, E2F transcription factors; BC, breast carcinoma; ER, estrogen receptor; IHC, immunohistochemistry; PR, progesterone receptor.